Trial · NCT04414475
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
NCT04414475, Phase 2, Recruiting, Karyopharm Therapeutics Inc
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. Trials, record NCT04414475. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04414475
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
- NCT number
- NCT04414475
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 127 participants, estimated
- Lead sponsor
- Karyopharm Therapeutics Inc
- Conditions
- Multiple Myeloma, Refractory
- Interventions
- Selinexor, Dexamethasone, Bortezomib
- First posted
- 2020-06-04
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Response Rate (ORR) | From the date of randomization up to death (approximately 60 months) | |
| Secondary | Duration of Response (DOR) | From the date of randomization to first disease progression or death (approximately 60 months) | |
| Secondary | Clinical Benefit Rate (CBR) | From the date of randomization up to death (approximately 60 months) | |
| Secondary | Disease control rate (DCR) | From the date of randomization up to death (approximately 60 months) | |
| Secondary | Progression-Free Survival (PFS) | From the date of randomization to first disease progression or death (approximately 60 months) | |
| Secondary | Overall Survival (OS) | From the date of randomization up to death (approximately 60 months) | |
| Secondary | Time to Next Treatment (TTNT) | From the date of first dose up to death (approximately 60 months) | |
| Secondary | Number of Participants with Adverse Events (AE) | From start of study drug administration up to follow-up (approximately 60 months) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 38826786 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04414475
GET https://conductscience.org/api/trials/v1/NCT04414475/registered